Pulmonary delivery of favipiravir inhalation solution for COVID-19 treatment: in vitro characterization, stability, in vitro cytotoxicity, and antiviral activity using real time cell analysis

• Κύριοι συγγραφείς: Ayca Yildiz Pekoz (Συγγραφέας), Ozlem Akbal Dagistan (Συγγραφέας), Hanan Fael (Συγγραφέας), Meltem Culha (Συγγραφέας), Aybige Erturk (Συγγραφέας), Nur Sena Basarir (Συγγραφέας), Gokben Sahin (Συγγραφέας), Muge Serhatli (Συγγραφέας), Gamze Cakirca (Συγγραφέας), Saban Tekin (Συγγραφέας), Leyla Semiha Sen (Συγγραφέας), Mustafa Sevim (Συγγραφέας), Lutfiye Mulazimoglu Durmusoglu (Συγγραφέας), Berrak C. Yegen (Συγγραφέας)
• Μορφή: Βιβλίο
• Έκδοση: Taylor & Francis Group, 2022-12-01T00:00:00Z.
• Θέματα: article
• Διαθέσιμο Online: Connect to this object online.

Favipiravir, an RNA-dependent RNA polymerase (RdRp) inhibitor, is used to treat patients infected with influenza virus and most recently with SARS-CoV-2. However, poor accumulation of favipiravir in lung tissue following oral administration has required an alternative method of administration that d...